{"schema_version":"secwatch.filing_event.v1","accession":"0001367644-25-000010","form_type":"8-K","ticker":"EBS","cik":"0001367644","company_name":"Emergent BioSolutions Inc.","filed_at":"2025-01-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.442275+00:00","generated_at":"2026-05-28T01:51:30.964621+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Emergent gains exclusive U.S./Canada commercial rights to Hikma's KLOXXADO 8 mg naloxone spray","bullets":["Six-year agreement gives Emergent exclusive rights to market and distribute KLOXXADO (naloxone HCl) 8 mg nasal spray in U.S. and Canada.","KLOXXADO complements existing OTC NARCAN 4 mg spray, offering higher-dose prescription option for opioid overdose reversal.","Hikma will continue manufacturing KLOXXADO; product will be integrated into Emergent's NARCANDirect distribution network.","CEO Joe Papa cites expanded product options to help reduce opioid overdose deaths and meet diverse patient and community needs."],"urls":{"canonical":"https://secwatch.observer/filing/0001367644-25-000010","json":"https://secwatch.observer/filing/0001367644-25-000010.json","markdown":"https://secwatch.observer/filing/0001367644-25-000010.md","text":"https://secwatch.observer/filing/0001367644-25-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367644/000136764425000010/0001367644-25-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367644/000136764425000010/ebs-20250114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T01:51:30.964621+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}